Cefmetazole Resistance Mechanism for Escherichia Coli Including ESBL-Producing Strains

References

• Paitan Y. Current trends in antimicrobial resistance of Escherichia coli. Curr Top Microbiol Immunol. 2018;416:181–211. PMID: 30088148. doi:10.1007/82_2018_110
   PubMed Web of Science ®Google Scholar
• Trautner BW, Darouiche RO. Role of biofilm in catheter-associated urinary tract infection. Am J Infect Control. 2004;32(3):177–183. PMID: 15153930; PMCID: PMC2963581. doi:10.1016/j.ajic.2003.08.005
   PubMed Web of Science ®Google Scholar
• Riley DK, Classen DC, Stevens LE, Burke JP. A large randomized clinical trial of a silver-impregnated urinary catheter: lack of efficacy and staphylococcal superinfection. Am J Med. 1995;98(4):349–356. PMID: 7709947. doi:10.1016/S0002-9343(99)80313-1
   PubMed Web of Science ®Google Scholar
• Pickard R, Lam T, Maclennan G, et al. Types of urethral catheter for reducing symptomatic urinary tract infections in hospitalised adults requiring short-term catheterisation: multicentre randomised controlled trial and economic evaluation of antimicrobial- and antiseptic-impregnated urethral catheters (the CATHETER trial). Health Technol Assess. 2012;16(47):1–197. PMID: 23199586. doi:10.3310/hta16470
   Web of Science ®Google Scholar
• Yougbaré S, Mutalik C, Okoro G, et al. Emerging trends in nanomaterials for antibacterial applications. Int J Nanomedicine. 2021;16:5831–5867. PMID: 34475754; PMCID: PMC8405884. doi:10.2147/IJN.S328767
   PubMed Web of Science ®Google Scholar
• Doi Y, Iovleva A, Bonomo RA. The ecology of extended-spectrum β-lactamases (ESBLs) in the developed world. J Travel Med. 2017;24(suppl_1):S44–S51. doi:10.1093/jtm/taw102
   PubMed Web of Science ®Google Scholar
• Toner L, Papa N, Aliyu SH, Dev H, Lawrentschuk N, Al-Hayek S. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in hospital urinary tract infections: incidence and antibiotic susceptibility profile over 9 years. World J Urol. 2016;34(7):1031–1037. PMID: 26511749. doi:10.1007/s00345-015-1718-x
   PubMed Web of Science ®Google Scholar
• Critchley IA, Cotroneo N, Pucci MJ, Jain A, Mendes RE. Resistance among urinary tract pathogens collected in Europe during 2018. J Glob Antimicrob Resist. 2020;23:439–444. PMID: 33212286. doi:10.1016/j.jgar.2020.10.020
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Yamamoto S, Takahashi S, et al. The third national Japanese antimicrobial susceptibility pattern surveillance program: bacterial isolates from complicated urinary tract infection patients. J Infect Chemother. 2020;26(5):418–428. PMID: 32081647. doi:10.1016/j.jiac.2020.01.004
   PubMed Web of Science ®Google Scholar
• Chong Y, Shimoda S, Yakushiji H, et al. Community spread of extended-spectrum β-lactamase-producing Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis: a long-term study in Japan. J Med Microbiol. 2013;62(Pt7):1038–1043. PMID: 23538565. doi:10.1099/jmm.0.059279-0
   PubMed Web of Science ®Google Scholar
• Doi Y, Park YS, Rivera JI, et al. Community-associated extended-spectrum β-lactamase-producing Escherichia coli infection in the United States. Clin Infect Dis. 2013;56(5):641–648. PMID: 23150211; PMCID: PMC3563390. doi:10.1093/cid/cis942
   PubMed Web of Science ®Google Scholar
• Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis. 2021;72(7):e169–e183. PMID: 33106864. doi:10.1093/cid/ciaa1478
   PubMed Web of Science ®Google Scholar
• Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother. 2012;67(12):2793–2803. PMID: 22915465. doi:10.1093/jac/dks301
   PubMed Web of Science ®Google Scholar
• Pangon B, Bizet C, Buré A, et al. In vivo selection of a cephamycin-resistant, porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 beta-lactamase. J Infect Dis. 1989;159(5):1005–1006. PMID: 2651531. doi:10.1093/infdis/159.5.1005
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 31st ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2021.
   Google Scholar
• Chetri S, Singha M, Bhowmik D, et al. Transcriptional response of OmpC and OmpF in Escherichia coli against differential gradient of carbapenem stress. BMC Res Notes. 2019;12(1):138. PMID: 30871640; PMCID: PMC6419367. doi:10.1186/s13104-019-4177-4
   PubMed Web of Science ®Google Scholar
• Haldorsen B, Aasnaes B, Dahl KH, et al. The AmpC phenotype in Norwegian clinical isolates of Escherichia coli is associated with an acquired ISEcp1-like ampC element or hyperproduction of the endogenous AmpC. J Antimicrob Chemother. 2008;62(4):694–702. PMID: 18583329. doi:10.1093/jac/dkn257
   PubMed Web of Science ®Google Scholar
• Paltansing S, Tengeler AC, Kraakman ME, Claas EC, Bernards AT. Exploring the contribution of efflux on the resistance to fluoroquinolones in clinical isolates of Escherichia coli. Microb Drug Resist. 2013;19(6):469–476. PMID: 23909485. doi:10.1089/mdr.2013.0058
   PubMed Web of Science ®Google Scholar
• Tomás M, Doumith M, Warner M, et al. Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother. 2010;54(5):2219–2224. PMID: 20194693; PMCID: PMC2863613. doi:10.1128/AAC.00816-09
   PubMed Web of Science ®Google Scholar
• Livermore DM, Warner M, Mushtaq S. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother. 2013;68(10):2286–2290. PMID: 23696619. doi:10.1093/jac/dkt178
   PubMed Web of Science ®Google Scholar
• Young K, Painter RE, Raghoobar SL, et al. In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa. BMC Microbiol. 2019;19(1):150. PMID: 31272373; PMCID: PMC6610938. doi:10.1186/s12866-019-1522-7
   PubMed Web of Science ®Google Scholar
• Livermore DM. Beta-lactamases in laboratory and clinical resistance. Clin Microbiol Rev. 1995;8(4):557–584. PMID: 8665470; PMCID: PMC172876. doi:10.1128/CMR.8.4.557
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Yamamoto M, Nagao M, Tanaka M, Takakura S, Ichiyama S. In vitro activities and detection performances of cefmetazole and flomoxef for extended-spectrum β-lactamase and plasmid-mediated AmpC β-lactamase-producing Enterobacteriaceae. Diagn Microbiol Infect Dis. 2016;84(4):322–327. PMID: 26782634. doi:10.1016/j.diagmicrobio.2015.12.001
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Gutiérrez B, Pérez-Galera S, Salamanca E, et al. A multinational, preregistered cohort study of β-Lactam/β-Lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2016;60(7):4159–4169. PMID: 27139473; PMCID: PMC4914653. doi:10.1128/AAC.00365-16
   PubMed Web of Science ®Google Scholar
• Tsutsui A, Yahara K, Shibayama K. Trends and patterns of national antimicrobial consumption in Japan from 2004 to 2016. J Infect Chemother. 2018;24(6):414–421. PMID: 29428566. doi:10.1016/j.jiac.2018.01.003
   PubMed Web of Science ®Google Scholar
• Ghai I, Ghai S. Understanding antibiotic resistance via outer membrane permeability. Infect Drug Resist. 2018;11:523–530. PMID: 29695921; PMCID: PMC5903844. doi:10.2147/IDR.S156995
   PubMed Web of Science ®Google Scholar
• Nikaido H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol Biol Rev. 2003;67(4):593–656. PMID: 14665678; PMCID: PMC309051. doi:10.1128/MMBR.67.4.593-656.2003
   PubMed Web of Science ®Google Scholar
• Nikaido H, Rosenberg EY, Foulds J. Porin channels in Escherichia coli: studies with beta-lactams in intact cells. J Bacteriol. 1983;153(1):232–240. PMID: 6294048; PMCID: PMC217361. doi:10.1128/jb.153.1.232-240.1983
   PubMed Web of Science ®Google Scholar
• Phoenix DA. On the targeting and membrane assembly of the Escherichia coli outer membrane porin, PhoE. FEMS Immunol Med Microbiol. 1996;16(2):77–82. PMID: 8988389. doi:10.1111/j.1574-695X.1996.tb00125.x
   PubMedGoogle Scholar
• Jacoby GA, Carreras I. Activities of beta-lactam antibiotics against Escherichia coli strains producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 1990;34(5):858–862. doi:10.1128/AAC.34.5.858
   PubMed Web of Science ®Google Scholar
• Delcour AH. Outer membrane permeability and antibiotic resistance. Biochim Biophys Acta. 2009;1794(5):808–816. PMID: 19100346; PMCID: PMC2696358. doi:10.1016/j.bbapap.2008.11.005
   PubMed Web of Science ®Google Scholar
• Ananthan S, Subha A. Cefoxitin resistance mediated by loss of a porin in clinical strains of Klebsiella pneumoniae and Escherichia coli. Indian J Med Microbiol. 2005;23(1):20–23. PMID: 15928416. doi:10.4103/0255-0857.13867
   PubMedGoogle Scholar
• Rowbury RJ, Goodson M, Wallace AD. The PhoE porin and transmission of the chemical stimulus for induction of acid resistance (acid habituation) in Escherichia coli. J Appl Bacteriol. 1992;72:233–243. doi:10.1111/j.1365-2672.1992.tb01829.x
   PubMedGoogle Scholar
• Berrier C, Coulombe A, Houssin C, Ghazi A. Voltage-dependent cationic channel of Escherichia coli. J Membr Biol. 1993;133:119–127. doi:10.1007/BF00233793
   PubMed Web of Science ®Google Scholar
• Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, Pascual A. Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae. Clin Microbiol Rev. 2018;31(2):e00079–17. doi:10.1128/CMR.00079-17
   PubMed Web of Science ®Google Scholar
• Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev. 2009;22:161–182. doi:10.1128/CMR.00036-08
   PubMed Web of Science ®Google Scholar
• Nelson EC, Elisha BG. Molecular basis of AmpC hyperproduction in clinical isolates of Escherichia coli. Antimicrob Agents Chemother. 1999;43(4):957–959. PMID: 10103209; PMCID: PMC89235. doi:10.1128/AAC.43.4.957
   PubMed Web of Science ®Google Scholar
• Caroff N, Espaze E, Gautreau D, Richet H, Reynaud A. Analysis of the effects of −42 and −32 ampC promoter mutations in clinical isolates of Escherichia coli hyperproducing ampC. J Antimicrob Chemother. 2000;45(6):783–788. PMID: 10837430. doi:10.1093/jac/45.6.783
   PubMed Web of Science ®Google Scholar
• Bialek-Davenet S, Marcon E, Leflon-Guibout V, et al. In vitro selection of ramR and soxR mutants overexpressing efflux systems by fluoroquinolones as well as cefoxitin in Klebsiella pneumoniae. Antimicrob Agents Chemother. 2011;55(6):2795–2802. PMID: 21464248; PMCID: PMC3101381. doi:10.1128/AAC.00156-11
   PubMed Web of Science ®Google Scholar
• Shlaes DM. New β-lactam-β-lactamase inhibitor combinations in clinical development. Ann N Y Acad Sci. 2013;1277:105–114. PMID: 23346860. doi:10.1111/nyas.12010
   PubMed Web of Science ®Google Scholar
• Goldstein EJC, Citron DM, Tyrrell KL, Leoncio E, Merriam CV. Comparative in vitro activities of relebactam, imipenem, the combination of the two, and six comparator antimicrobial agents against 432 strains of anaerobic organisms, including imipenem-resistant strains. Antimicrob Agents Chemother. 2018;62(2):e01992–17. PMID: 29158284; PMCID: PMC5786751. doi:10.1128/AAC.01992-17
   PubMed Web of Science ®Google Scholar
• Yin H, Guiying L, Chen X, et al. Accelerated evolution of bacterial antibiotic resistance through early emerged stress responses driven by photocatalytic oxidation. Appl Catal B. 2020;269:118829. doi:10.1016/j.apcatb.2020.118829
   Web of Science ®Google Scholar
• Chen M, Cai Y, Guiying L, Zhao H, Taicheng AN. The stress response mechanisms of biofilm formation under sub-lethal photocatalysis. Appl Catal B. 2022;307:121200. doi:10.1016/j.apcatb.2022.121200
   Web of Science ®Google Scholar